Source: Annual Congress 2007 - Novel genetic markers in pathology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Fijolek, E. Wiatr, E. Rowinska-Zakrzewska, R. Langfort, T. Orlowski (Warsaw, Poland). p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Eur Respir J 2007; 30: Suppl. 51, 3215

Member's Comments

No comment yet.

Related content which might interest you: Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001 Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Relation between ERCC1 expression in sputum and survival after cisplatin-based chemotherapy in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016